Abstract: The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least there identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.

Abstract: The invention relates to a computer-implemented method for classifying events present in a sample, wherein each event is characterized by a multidimensional set of parameters obtained by means of hardware and/or software, wherein the values of the parameters associated with each event define the position coordinates of said event in a multidimensional space. Said method comprises the following stages: a) clustering the events in groups, b) checking if within each formed group there is a connection between events exceeding a maximum distance threshold, c) calculating the affinity between each pair of previously generated sample groups, d) comparing each sample group with at least one reference group stored in at least one database, e) classifying the sample groups based on the comparisons with the reference groups.

Abstract: The invention relates to the field of minimal residual disease (MRD) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic leukemia (B-CLL), and multiple myeloma (MM). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for ?8-color flow cytometric stainings as well as for 10-color and 12-color flow cyometric stainings, which can reach sensitivities of at least 10?4, even down to 10?5. Also provided are diagnostic kits and methods for detecting MRD.

Abstract: The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least there identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.

Abstract: The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least three identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.

Abstract: The invention relates to the field of medical diagnostics. In particular, it relates method and kits for identification and classification of IgE-related diseases, e.g. Type I hypersensitivity, as well as for monitoring of treatment efficacy, for instance anti-IgE therapy.

Abstract: This invention relates to methods to detect the presence of cancer infiltration of the Central Nervous System (CNS) based on the detection of soluble proteins, preferably, in cerebrospinal fluid samples and vitreous fluid. The invention also relates to kits to perform the methods of the invention.

Abstract: The invention relates to the field of minimal residual disease (MRD) diagnostics, which is progressively more applied for the evaluation of treatment effectiveness in patients with a hematological malignancy, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL), B-cell chronic lymphocytic leukemia (B-CLL), and multiple myeloma (MM). Provided are unique reagent compositions with carefully selected and thoroughly tested combinations of antibodies, for ?8-color flow cytometric stainings as well as for 10-color and 12-color flow cytometric stainings, which can reach sensitivities of at least 10?4, even down to 10?5. Also provided are diagnostic kits and methods for detecting MRD.

Abstract: The invention relates to the field of medical diagnostics. In particular, it relates method and kits for identification and classification of IgE-related diseases, e.g. Type I hypersensitivity, as well as for monitoring of treatment efficacy, for instance anti-IgE therapy.

Abstract: The invention relates to the field of medical diagnostics. Provided are methods and kits for determining the health status of a subject, for early detection of tissue damage, for early diagnosis and monitoring of a disease, and/or for evaluation of treatment effectiveness in a subject using circulating tissue macrophages (CTM) as a mirror of disrupted tissue homeostasis and disease.

Abstract: This invention relates to methods to detect the presence of cancer infiltration of the Central Nervous System (CNS) based on the detection of soluble proteins, preferably, in cerebrospinal fluid samples and vitreous fluid. The invention also relates to kits to perform the methods of the invention.

Abstract: The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least three identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.

Abstract: This invention relates to the detection of among others tumor-specific fusion proteins and protein interactions. Provided is a set of at least a first and a second molecular probe, each probe provided with a dye wherein said dyes together allow energy transfer, each probe additionally provided with a reactive group allowing juxtaposing said at least first and second probe, wherein said reactive group is an oligonucleotide and wherein the reactive group of said first probe is not directly reactive with the reactive group of said second probe.

Abstract: A single measurement can quantify phosphatidyl-inositol glycan complementation class A (PIG-A) associated proteins in red cells, platelets and the major leukocyte subsets present in blood (lymphocytes, monocytes, neutrophils and eosinophils). The single measurement relies on flow cytometry to simultaneously evaluate intensity of fluorochrome emissions and light scattering properties.

Abstract: A method that generates new flow cytometry data files with a potentially infinite number of dimensions is described. First two or more separate flow cytometry data files containing information about events measured in different aliquots from the same sample are fused. Then, the magnitude of the values and a corresponding uncertainty measure of the differing variables between one or more of the original data files which have been fused are estimated, for each individual event contained in the fused data file, for which that variable was not directly measured in the flow cytometer. The new data file containing both data actually measured in the flow cytometer for each event of the individual original data files fused and the estimated data for those parameters not measured in a group of events from one or more of the original data files are reconstructed multidimensionally.

Abstract: Procedure for controlling the enumeration of the absolute count of cells (or other particles) present in a sample.

Abstract: Procedure for controlling the enumeration of the absolute count of cells (or other particles) present in a sample.